Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On February 18, 2026, Dr. Steve N. Slilaty, as the holder of the majority of the voting power of the stockholders of Sunshine Biopharma Inc. (the "Company"), approved by written consent authorizing the Company's board of directors to effect a reverse split of the Company's issued and outstanding common stock in a ratio of up to 1-for-10, with the board of directors having the discretion as to whether or not the reverse split is to be effected, and with the exact ratio of any reverse split to be set at a whole number up to 1-for-10 as determined by the board in its discretion. The shareholder consent will be effective 20 days after the definitive information statement relating to such consent is mailed to stockholders. Dr. Slilaty, who is the Company's chief executive officer, holds approximately 96% of the total voting power of the Company's stockholders.